Can-Fite BioPharma Ltd. SEC Filing Summary

Can-Fite BioPharma Ltd. announced that the Israeli Patent Office has allowed its patent application for Namodenoson, a drug targeting obesity and related metabolic disorders. This patent strengthens the company's global intellectual property portfolio, adding to similar allowances in the US, Canada, and Australia. The company highlights Namodenoson's potential as a differentiated treatment for the growing obesity market, citing its unique mechanism of action and favorable safety profile. The global obesity therapeutics market is projected to reach $60.5 billion by 2030. Namodenoson is also being evaluated for liver cancer and other indications. The filing also includes standard forward-looking statements and risk factors associated with the company's operations and the pharmaceutical industry.